Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of baricitinib in systemic lupus erythematosus
CTR20190368Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in systemic lupus erythematosus (SLE), sponsored by Eli Lilly and Company. Started Mar 2019; status: terminated.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20190368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190368.